Skip to main content

Table 2 Association of ACE gene D/I polymorphism with variables used as markers of severity of CF, patients followed at the pediatric center in UNICAMP distributed by CFTR gene mutation identified divided into cohorts

From: The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis

Variable

Without taking CFTRmutation into account

No identified mutation

One identified mutation

Two identified mutation

E

p

E

p

E

p

E

p

Patients age

W:0.791

0.374

W:3x10-5

0.995

W:2.969

0.085

W:0.001

0.984

Onset of clinical manifestations

W:0.116

0.733

W:0.162

0.687

W:4.29

0.038

W:0.937

0.333

Diagnostic

W:0.11

0.74

W:0.047

0.83

W:0.099

0.753

W:0.087

0.768

Onset of digestive symptons

W:1.494

0.221

W:0.148

0.7

W:0.297

0.586

W:0.979

0.322

Onset of lung symptons

W:0.021

0.885

W:0.039

0.843

W:0.401

0.526

W:1.302

0.31

BMI

W:1.169

0.28

W:0.687

0.407

W:0.436

0.509

W:2.498

0.114

Nasal poliposys

W:0.62

0.431

W:0.984

0.321

W:0.419

0.517

W:1.26

0.262

Diabetes

W:0.358

0.55

W:0.016

0.901

W:0.174

0.676

W:0.184

0.668

Osteoporosis

W:0.877

0.349

W:1.056

0.0304

W:0.561

0.454

W:0.083

0.773

Pancreatic insuficience

W:1.6

0.206

W:0.693

0.406

W:1.063

0.302

W:0.182

0.669

Meconium ileus

W-0.252

0.616

W:3.813

0.051

W:1.109

0.292

W:1.498

0.221

SaO2

F:2.131

0.142

F:0.022

0.884

F:1.868

0.178

F:1.344

0.25

Scores

Bhalla

F:6.526

0.012

F:0.2

0.689

F:4.942

0.032

F:4.013

0.049

Kanga

F:1.3

0.256

F:0.486

0.492

F:0.027

0.871

F:3.765

0.057

SK

F:2.361

0.127

F:0.286

0.597

F:1.042

0.312

F:1.243

0.269

FVC

F:0.139

0.71

F:0.829

0.37

F:0.918

0.345

F:0.93

0.339

FEV1

F:0.785

0.377

F:0.622

0.436

F:0.907

0.348

F:2.797

0.099

FEV1/FVC

F:0.891

0.347

F:0.005

0.943

F:2.212

0.146

F:0.156

0.694

FEF25-75%

F:0.42

0.518

F:0.112

0.735

F:0.02

0.887

F:1.048

0.31

1a P. aeruginosa isolated

W:0.962

0.327

W:0.702

0.402

W:0.16

0.69

W:0.099

0.753

Isolated Bacteria

PAM

W:0.92

0.338

W:0.141

0.708

W:2.016

0.156

W:0.165

0.684

PANM

W:1.21

0.272

W:1.149

0.284

W:0.987

0.753

W:0.262

0.609

AX

W:3.2

0.074

W:0.038

0.845

W:0.642

0.423

W:2.911

0.088

BC

W:4.290

0.038

W:0.1

0.753

W:3.681

0.055

W:0.341

0.559

SA

W:0.209

0.65

W:1.151

0.283

W:0.191

0.662

W:1.102

0.294

  1. Analysis by linear regression (F) and logistic regression (W) test . Values below of 0.05 for p denote a clinical correlation between variables. E - Statistical,% - percentage, SaO2 - transcutaneous oxygen saturation, FEV1 – forced expiratory volume in 1 second, FVC – forced expiratory capacity, FEV1/FVC – ratio between two variables, forced FEF25-75, SC - expiratory flow at 25-75% of the pulmonary volume, SK - Shwachman-Kulczycki, PAM – P. aeruginosa mucoid, PAM – P. aeruginosa non mucoid, AX – A. xylosoxidans, BC – B. cepacia, SA – S. aureus, BMI – body mass index, CF - cystic fibrosis, ACE – angiotensin converting enzyme. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II and/or III. Others identified mutations as class IV (P205S e R334W) was included in the statistical analysis in the not identified mutation subgroup, to minimize the associated factor with the mutation classes in the CFTR gene.